Literature DB >> 12657315

The role of phospholipases A2 in the stimulation of neutrophil motility by cobra venoms.

I Birgitta Sundell1, Khalil A Aziz, Mirko Zuzel, R David G Theakston.   

Abstract

Neutrophil (PMN) accumulation frequently occurs at the site of snakebite as part of the inflammatory response to envenoming. We demonstrate here that the venoms of the cobras, Naja naja and N. mossambica, and two purified venom phospholipase A(2)s (PLA(2)s) isolated from the latter venom, stimulate CD11b translocation from the PMN granule store to the plasma membrane and enhance neutrophil motility on collagen-coated surfaces. These effects were partially attenuated by the PLA(2) inhibitor, aristolochic acid, and almost completely abolished by the specific cytosolic PLA(2) inhibitor, methylarachidonylfluorophosphonate (MAFP). Annexin V and inhibitors of collagenase, cyclo-oxygenase and lipo-oxygenase, all inhibited PMN motility to a variable extent. FACS analysis and confocal microscopy showed that Annexin V interfered with binding and rapid endocytosis of the venom PLA(2). These results indicate that venom and venom PLA(2) preparations first caused a non-enzymatic stimulation of PMN leading to the activation of cytosolic PMN PLA(2) and production of arachidonate metabolites involved in stimulation of PMN degranulation and motility. The evidence suggests that venom PLA(2) then interacts with anionic phospholipids exposed on stimulated PMN, becomes endocytosed, and then contributes itself to the production of chemoattractants responsible for PMN accumulation at the site of the snakebite.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657315     DOI: 10.1016/s0041-0101(02)00365-3

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  1 in total

Review 1.  Biological Effects of Animal Venoms on the Human Immune System.

Authors:  Zharick Avalo; María Claudia Barrera; Manuela Agudelo-Delgado; Gabriel J Tobón; Carlos A Cañas
Journal:  Toxins (Basel)       Date:  2022-05-16       Impact factor: 5.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.